ReviewHuman vaccines & immunotherapeutics2012
Recombinant allergens: the present and the future.
Review in Human vaccines & immunotherapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 37 citations in OpenAlex.
- Lessons learned from allergen adsorption on engineered nanomaterials: bridging experimental insights and computational technologies.Nanomedicine (London, England) · 2026Review
- Comparison of Skin Prick Tests (SPT), Intradermal Tests (IDT) andAnimals : an open access journal from MDPI · 2023Article
- Selected Technical Aspects of Molecular Allergy Diagnostics.Current issues in molecular biology · 2023Review
- Egg Allergy: Diagnosis and Immunotherapy.International journal of molecular sciences · 2020Review
- Review
- A review of clinical efficacy, safety, new developments and adherence to allergen-specific immunotherapy in patients with allergic rhinitis caused by allergy to ragweed pollen (Patient preference and adherence · 2017Review
- Molecular allergy diagnostic tests: development and relevance in clinical practice.Allergologie select · 2017Review
- Allergen Immunotherapy: Past, Present, and Future.Allergy, asthma & immunology research · 2016Review
- Molecular biomarkers for grass pollen immunotherapy.World journal of methodology · 2014Review
- Allergen-Specific Immunotherapy in Asthma.Current treatment options in allergy · 2014Review
- Cloning, expression, and analysis of a cDNA coding for the Dermatophagoides farinae group 21 (Der f 21) allergen.American journal of translational research · 2014Article
- Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy.Current treatment options in allergy · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergen specific immunotherapy (SIT) is the only known causative treatment of allergic diseases. Recombinant allergen-based vaccination strategies arose from a strong need to both to improve safety and enhance efficacy of SIT. In addition, new vaccines can be effective in allergies including food allergy or atopic dermatitis, which poorly respond to the current treatment with allergen extracts. A number of successful clinical studies with both wild-type and hypoallergenic derivatives of recombinant allergens vaccines have been reported for the last decade. They showed high efficacy and safety profile as well as very strong modulation of T and B cell responses to specific allergens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.